USANA Health Sciences shares preliminary FY 2026 net sales outlook

USANA Health Sciences, Inc. reported that it has issued a press release with preliminary net sales for the full fiscal year ended January 3, 2026.

Accepted by SEC EDGAR 01/12/2026 - 06:29 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

USANA Health Sciences, Inc. reported that it has issued a press release with preliminary net sales for the full fiscal year ended January 3, 2026. The company also provided net sales guidance for its currently expected financial results for the fiscal year ending January 2, 2027. This information is furnished under Items 2.02 and 7.01 and is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Exchange Act and is not incorporated by reference into Securities Act registration statements.

Insights

Equity disclosure analyst

USANA furnishes preliminary annual sales and next-year guidance via press release.

USANA Health Sciences, Inc. has provided an early look at its performance for the fiscal year ended January 3, 2026 by releasing preliminary net sales, along with net sales guidance for the fiscal year ending January 2, 2027. These types of disclosures help frame expectations for the upcoming annual report and the next fiscal year, even though specific figures are only available in the attached press release.

The company is furnishing this information under Items 2.02 and 7.01, explicitly stating it is not deemed filed under the Exchange Act and will not be incorporated by reference into Securities Act registration statements. That structure keeps the disclosure within Regulation FD practices while limiting certain legal liabilities. The actual impact on investors will depend on the detailed numbers and guidance ranges contained in Exhibit 99.1.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did USANA Health Sciences (USNA) announce in this 8-K?

USANA Health Sciences announced that it issued a press release with preliminary net sales for the fiscal year ended January 3, 2026 and net sales guidance for the fiscal year ending January 2, 2027.

Which fiscal periods are covered by USANAs latest net sales update?

The update covers preliminary net sales for the full fiscal year ended January 3, 2026 and provides net sales guidance for the fiscal year ending January 2, 2027.

How did USANA Health Sciences (USNA) provide its preliminary sales and guidance information?

USANA provided the information through a press release dated January 12, 2026, which is furnished as Exhibit 99.1 to this report.

Is the USANA preliminary net sales information considered filed with the SEC?

No. USANA states that the information in this report, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

Does USANA incorporate this preliminary sales information into its registration statements?

USANA specifies that the information in this report, including the exhibits, shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933.

Under which SEC items did USANA furnish this disclosure?

The company furnished this disclosure under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FALSE000089626400008962642026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 12, 2026

USANA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of incorporation)

001-35024			87-0500306
(Commission File No.)			(IRS Employer Identification No.)

3838 West Parkway Boulevard

Salt Lake City, Utah 84120

(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			USNA			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On January 12, 2026, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing preliminary net sales for the full fiscal year ended January 3, 2026, and net sales guidance with respect to the Company's currently expected financial results for the fiscal year ending January 2, 2027. A copy of this press release is attached hereto as Exhibit 99.1

The information, including Exhibit 99.1, in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available

Item 7.01    Regulation FD Disclosure

On January 12, 2026, the Company issued a press release announcing preliminary net sales for the fiscal year ended

January 3, 2026 along with initial net sales guidance for fiscal year 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press release issued by USANA Health Sciences, Inc. dated January 12, 2026 (furnished herewith).
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			USANA HEALTH SCIENCES, INC.
			By:			/s/ G. Douglas Hekking
			G. Douglas Hekking, Chief Financial Officer
Date: January 12, 2026